Security key
114082209
Ernexa Therapeutics Inc. - Common Stock (ERNA)
CUSIP: 114082209
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 994,393
- Total 13F value
- $292,358
- Share change
- +272,071
- SEC-reported price per share
- $0.29
- Number of holders
- 24
- Value change
- +$69,713
- Number of buys
- 8
- Number of sells
- 8
- Shares outstanding
- 1,166,181
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
24
Top holders
10
ERNA full security history
Ownership snapshot
Full 13F holder table
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ERNA - Ernexa Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nicholas J. Singer
Disclosed value leader
Nicholas J. Singer
Comparable rows
15/15
Latest evidence
30 Sep 2024
3/4/5
13D/G
13F
Lead comparable stake: 4.9%
13D/G row: Nicholas J. Singer
Showing 1-6 of 15 holder rows.
Quick read
Nicholas J. Singer leads the comparable SEC ownership view at 4.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nicholas J. Singer's linked filing trail.
Comparable ownership
Top 5
Nicholas J. Singer
4.9%
Corient Private Wealth LLC
23%
Cypress Point Wealth Management, LLC
8.1%
UBS Group AG
7.2%
Naviter Wealth, LLC
6.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nicholas J. Singer |
3/4/5
13D/G
Director · Nicholas Jason Singer
|
4.9%
from 13D/G
|
$962,330
954,608 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Corient Private Wealth LLC |
13F
Company
|
23%
|
$276,005
262,862 shares
|
— | 30 Sep 2024 |
| Cypress Point Wealth Management, LLC |
13F
Company
|
8.1%
|
$99,094
94,375 shares
|
— | 30 Sep 2024 |
| UBS Group AG |
13F
Company
|
7.2%
|
$87,801
83,620 shares
|
— | 30 Sep 2024 |
| Naviter Wealth, LLC |
13F
Company
|
6.8%
|
$82,736
78,796 shares
|
— | 30 Sep 2024 |
| Sippican Capital Advisors |
13F
Company
|
5.9%
|
$71,929
68,504 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
24
Shares
994,393
Rows available
24
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
20
Q4 2024 holders
24
Holder diff
4
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|